Precision dosing for breastfeeding mothers on opioid treatment
Official title: Integrating A Novel Human Mammary Epithelium Assay with Mother-Infant PBPK-PD Modeling for Precision Dosing of OUD Medications in Lactating Mothers
Funded at State University of Ny,binghamton · NIH-11339865 · Data updated 2026-11-12
Aims to build a model-guided method to predict drug exposure for mothers with opioid use disorder and their breastfed babies to support safer dosing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of Ny,binghamton NIH-funded |
| Lab location | 1 site (Binghamton, United States) |
| Project start | August 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $689,676 |
| NIH project number | 1R01DA065561-01 |
| Project ID | NIH-11339865 on NIH RePORTER |
Who could benefit from this research
✓Could help
Lactating mothers receiving medication-assisted treatment for opioid use disorder and their breastfeeding infants.
✕Less likely to help
Pregnant or non-lactating individuals and those not on MAT are unlikely to benefit from this study.
What this research studies
This project creates a lactation-specific, human mammary barrier model and combines it with real-world data from breastfeeding mothers on MAT to predict how drugs pass into breast milk and affect infants. Researchers will gather paired blood and milk samples, develop PBPK models, and integrate infant health markers to forecast exposure for different formulations. The work blends lab models, clinical samples, and computer simulations to produce practical dosing guidance for lactating women who are treated for OUD. The goal is to give clinicians and families clearer information to minimize infant exposure while maintaining maternal treatment efficacy.
Why it matters
Potential benefit: If successful, the project could lead to safer, more precise dosing of OUD medications during breastfeeding, protecting infant health while supporting maternal recovery.
How similar studies have gone: Previous work has shown that integrating lab models with clinical data can improve exposure predictions, but this approach is novel in the context of lactation and OUD medications.
Where this research is happening
-
State University of Ny,binghamton
Binghamton, United States Active
Researchers
- Principal investigator: Zhang, Tao — State University of Ny,binghamton
- Study coordinator: Zhang, Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.